Trial ID or NCT#
NCT00946673
Status
NOT RECRUITING
Purpose
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4 lesions.
Official Title
A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Iris C. Gibbs, MD, FACR, FASTRO
Radiation oncologist,
Neuro-oncologist
Professor of Radiation Oncology (Radiation Therapy)
Scott G. Soltys, MD
Radiation oncologist
Associate Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Joel Neal, MD, PhD
Medical oncologist,
Thoracic specialist
Associate Professor of Medicine (Oncology)
Steven D. Chang, MD
Neurosurgeon,
Aneurysm neurosurgeon,
Cerebrovascular neurosurgeon,
Pituitary tumors neurosurgeon,
Stereotactic neurosurgeon
Robert C. and Jeannette Powell Neurosciences Professor and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology
Contact us to find out if this trial is right for you.
CONTACT
Ccto-office@stanford.edu
(650) 498-7061
View on ClinicalTrials.gov